CPSE:NOVO BPharmaceuticals
Oral Wegovy’s Record U.S. Launch Might Change The Case For Investing In Novo Nordisk (CPSE:NOVO B)
Novo Nordisk recently reported first‑quarter 2026 results showing sales rising to DKK 96,823 million and net income to DKK 48,557 million, driven largely by surging demand for its new oral Wegovy weight‑loss pill, which has passed two million U.S. prescriptions since its January launch.
This launch is being described as the strongest-ever U.S. obesity drug debut by volume, prompting Novo Nordisk to raise its 2026 guidance for adjusted sales and operating profit as oral GLP‑1 treatments...